At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study for Patients with Acute Myeloid Leukemia

Clinical Trial Title: 
A phase III randomized trial for patients with de novo AML using bortezomib and sorafenib (IND# I14480, NSC# 681239, NSC# 724772) for patients with high allelic ratio FLT3/ITD.
Clinical Trial Protocol ID: 
11062301-CAO I
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To compare event free survival (EFS) and overall survival (OS) in patients with de nova acute myeloid leukemia (AML) without high allelic ratio FLT3/ITD+mutations who are randomized to standard therapy versus bortezomib/standard combination therapy.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are less that 30 years of age at the time of study enrollment.
  • Have been newly diagnosed with de novo acute myelogenous leukemia.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office